

control of the exogenous regulatory sequence, so that the homologously recombinant cell produces the therapeutic product. ✓

REMARKS


Applicants point out that a typographical error was made in the first Preliminary Amendment filed with the above-referenced application on January 6, 1999. Applicants had intended to cancel claims 2-57 and keep only claim 1 pending in the application for filing purposes, as evidenced in the remarks section on the attached copy of the first Preliminary Amendment; however, due to a typographical error, the first Preliminary Amendment stated that claims 2-37 were being cancelled. The present amendment explicitly states that claims 38-57 are being cancelled, in order to remove any ambiguity about whether the first Preliminary Amendment accomplished that. In addition, claim 1 is now cancelled and new claims 58-65 added.

A check in the amount of \$390.00 to cover excess claims fees for the newly added claims is enclosed.

Please charge any other fees, or make any credits, to
Deposit Account No. 06-1050.

Date: March 31, 1999

Respectfully submitted,


Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804

Telephone: 617/542-5070
Facsimile: 617/542-8906
365147.B11